-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on Viking Therapeutics, Lowers Price Target to $106

Benzinga·10/20/2026 15:33:59
Listen to the news
Canaccord Genuity analyst Edward Nash maintains Viking Therapeutics (NASDAQ:VKTX) with a Buy and lowers the price target from $114 to $106.